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Background: Fluoroscopically guided lumbar cortisone injections have been proven useful in 
cases of lower-limb pain caused by lumbar disc prolapse (with evidence levels ll-1/ll-2). These 
injections are also sometimes used clinically in sports medicine for patients with non-specific 
exercise-related lower-limb pain, where no prolapse or other obvious cause of nerve-impingement 
is diagnosed via magnetic resonance imaging (MRI) or computed tomography (CT), even though 
this treatment scenario has not been adequately studied for this last diagnosis.
Objectives: To explore whether fluoroscopically guided transforaminal lumbar cortisone injec-
tions may be a valid treatment method for non-specific exercise-related lower-limb pain.
Study design: Retrospective case series.
Methods: Patients were selected from databases at two sports clinics and divided into 
two groups: Group D, with back-related lower-limb pain and disc prolapse proven on CT or 
MR; and Group N, with non-specific exercise-related lower-limb pain. Patients were sent a 
questionnaire regarding: symptoms, improvement, effect of injections, satisfaction, side effects 
and other used treatments. Outcomes were compared between Group D and N.
Results: 153 patients were eligible for the study (Group D: 93/Group N: 60). Eventually 
110 patients responded (Group D: 67/Group N: 43). Twelve percent of Group D and 14% of Group 
N indicated that the injections had fully cured their symptoms. Altogether, 27% of Group D and 
24% of Group N were certain the injections had improved their symptoms in the long term. A 
larger proportion however, indicated that the injection had certainly improved their symptoms 
in the short term, but noted that the effects were non-lasting (Group D: 28%/Group N: 30%). 
Two patients were certain the injections had actually worsened their symptoms. No significant 
differences in characteristics and outcomes between Group D and Group N were noted.
Conclusions: Outcomes of this study suggest fluoroscopically guided lumbar cortisone injec-
tions may have similar outcomes in patients with non-specific exercise-related lower-limb pain 
compared to patients with disc prolapse proven on MRI or CT causing back-related lower-limb 
pain. This might suggest a potential role for these injections in the treatment of non-specific 
exercise-related lower-limb pain. It should be noted that this is a low level of evidence study 
(level 3) and further study is warranted.
Keywords: back-related lower-limb pain, fluoroscopically guided cortisone injections
Introduction
Exercise-related lower-limb pain, that is pain during or after exercise, is common in 
sport. On most occasions, a specific anatomical diagnosis of injury can be made in the 
lower-limb itself (eg, hamstring or calf pain proven to be a muscle strain on magnetic 
resonance imaging [MRI]). However, some athletes and exercising individuals develop 
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(A) Determination of appropriate needle position 
(B) Contrast injected and checked for appropriate spread 
(C) Cortisone injection 
Figure 1 The procedure. The injection procedure was performed in a sterile 
room. Local anesthesia was given before the actual injection. For the injection, a 
spinal needle was used under fluoroscopic guidance. The needle was placed in the 
superior and anterior aspect of the corresponding neuroforamen. After the needle 
was determined radiographically to be in the appropriate position (A), contrast 
material was injected to document appropriate contrast spread along the spinal 
nerve into the epidural space without intravascular uptake (B). Next, a combination 
of cortisone with lidocaine was injected (C). The determination in Figure 1(A) is 
done on the screen (which is shown) correlating with the needle tip (which cannot 
be seen in the picture and therefore arrowed, as it is too small).
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 exercise-related lower-limb pain which is vague in nature and 
without specific pathology in the lower-limbs.1
In these cases, MRI or computed tomography (CT) 
of the lumbar spine sometimes reveals a disc prolapse. 
Although it is a controversial paradigm, as no specific 
mechanism has ever been proven for such an injury, many 
clinicians subscribe to the concept of a back-related 
hamstring injury as a cause of hamstring pain.1–3 When 
no specific pathology is found in the lower-limbs but pro-
lapse is found on MRI/CT of the lower back, disc prolapse 
becomes the working diagnosis. For such cases, fluoro-
scopically guided cortisone injections around the lumbar 
nerve roots have shown to be helpful with evidence levels 
of ll-1 for short-term (,6 months) and ll-2 for long-term 
(.6 months) relief.4,5
In a sports medicine setting in Australia, we have 
anecdotally experienced good clinical results using the 
same injections to the lumbar spine for the treatment of 
 exercise-related lower-limb pain, including when prolapse 
or other definite cause of nerve-impingement was not 
established on MRI/CT. The symptoms may be caused 
by slight irritation of the nerve-roots by other tissues sur-
rounding the nerve-root which is not shown on MRI/CT. 
This is interesting as despite no certain cause of nerve 
impingement being shown in the lumbar spine, treating 
the injury as a back-related condition has seemed to work 
in a fair number of cases.
While there remains no high-quality evidence to  suggest 
that there is a valid link between this treatment and the  success 
rate for this group of patients, in practice, our sports clinics 
have found that this treatment is quite successful.2 This needs 
further examination, which was the goal of this study: explor-
ing whether fluoroscopically guided spinal steroid injections 
in patients with non-specific exercise-related lower-limb pain 
is similarly successful, compared to the same injections for a 
group of patients (with confirmed prolapse on MRI/CT) for 
which these injections have already been proven to be useful. 
As such, a purpose of this comparison was to explore whether 
fluoroscopically guided lumbar cortisone injections are 
potentially helpful for pain relief in patients with non-specific 
exercise-related lower-limb pain, in the medium to long term 
(.6 months).
Methods
This study was conducted as a retrospective case series. 
Patients were initially selected from the database of 2 Sydney 
based sports physicians if they had been referred for and 
received a fluoroscopically guided transforaminal lumbar 
cortisone at spinal levels from L3–4 to L5–S1 between 
December 2002 and December 2007 for the treatment of 
lower-limb pain.
All of the injections (Figure 1) were performed by 
1 of 3 radiologists at either Sydney X Ray or the Mater 
Hospital, both located in Sydney. Each of the radiolo-
gists had over 10 years of experience and used the same 
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Table 1 Group comparisons between eligible patients and those successfully followed-up
Total Group D Group N
Initial  
group 
(n = 153)
Follow-up 
(n = 110)
P (+SE) Initial 
group 
(n = 93)
Follow-up 
(n = 67)
P (+SE) Initial 
group 
(n = 60)
Follow-up 
(n = 43)
P (+SE)
Age (years) 42.9 43 0.21 
(0.95)
40.6 41 0.85  
(2.05)
46.7 46 0.79  
(2.63)
Male 110 (72%) 76 (69%) 0.59 67 (72%) 46 (69%) 0.90 43 (72%) 30 (70%) 1.00
Elite athlete 54 (35%) 43 (39%) 0.61 33 (36%) 29 (43%) 0.55 21 (34%) 14 (33%) 1.00
Total number of athletes 118 (77%) 87 (78%) 0.88 70 (75%) 51 (76%) 1.00 48 (80%) 36 (84%) 0.88
Length of follow-up (months) 31.9 30.0 0.40 (2.25) 31.5 30.0 0.60 (2.88) 33.1 33.0 0.98 (3.60)
Abbreviations: SD, standard deviation; SE, standard error.
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technology in conducting the procedure. Only patients 
referred by either of 2 sports physicians and treated by 
any of 3 radiologists were included to minimize inconsis-
tency in the reason for referral and manner of injection 
technique.
December 2002 was chosen as the starting date for the 
cohort as this was the earliest date for which full computer 
records were available to check procedures conducted at the 
clinics. December 2007 was chosen as the end date to allow 
for a minimum of 12 months follow-up post-injection at the 
time of the start of the study.
Chart review was performed on the selected patients. 
The information collected included: patient characteristics 
(Table 1), specific lower-limb pathology, symptoms prior to 
the injections, and outcomes of MRI and CT scans includ-
ing etiology of any sciatica (stenosis/prolapse/unknown) and 
level of pathology.
Patients under the age of 18 years old, or suffering a 
specific lower-limb pathology that was subsequently discov-
ered on MRI or CT as being responsible for their pain, were 
excluded. The latter were excluded in order to keep the study 
focused specifically on cases with lower-limb pain presum-
ably caused by pathology in the lower back. In this way, 153 
patients were eligible for the study.
Patients were split based on chart and radiology review 
into Group D (95 patients) and Group N (58 patients). Group 
D consisted of patients whose primary diagnosis after lumbar 
MRI or CT scan was disc prolapse, presumed to be causing 
lower-limb pain. Group N consisted of patients whose primary 
diagnosis was non-specific exercise-related lower-limb pain; 
patients with suspected lower-back-related lower-limb pain 
but without prolapse on MRI or CT. Patients in Group N typi-
cally had vague exercise-related hamstring and/or calf pain.
Included patients were sent a questionnaire in December 
2008 and were able to complete the questionnaire either on 
paper or on an internet site designed for this specific pur-
pose. None of the patients who eventually replied objected to 
having their data used in our study. The study protocol was 
approved by the Human Ethics Research Committee of the 
University of Sydney.
The questionnaire was developed to assess several aspects 
of the medium-long-term effects of the injections. It comprised 
7 multiple-choice questions with the possibility to file a writ-
ten answer. Questions 1 and 2 related to specific symptoms 
in several areas of the lower-limbs and the lower back, while 
question 3 asked about the overall improvement of symptoms. 
Question 4 was designed to extract information on the extent 
to which the injections had a direct result on the improve-
ment of symptoms. Question 7 asked whether the patients 
would have the same procedure done for the same symptoms, 
knowing what they now know. The answers to questions 3, 
4 and 7 were combined to get a view on what the effect of 
the injections on the improvement of symptoms was, in the 
opinion of the patients. Question 5 asked whether side effects 
were experienced and question 6 aimed to exclude any other 
treatments that might have had an influence on the outcome 
of this study.
After collection and analysis of the answers, the 
improvement, the effect of the injections on the improve-
ment, the satisfaction of the patients, side effects and 
other treatments could be compared between the main 
Groups (D and N) and between the subgroups: male/
female, elite/non-elite, and older/younger than 30 years 
of age.
The comparisons of answers to the questionnaire 
and of patient characteristics were done using Fisher’s 
exact tests and two-tailed t-tests in setting significance 
at P , 0.05. Online GraphPad© software was used for 
this purpose.
Results
Initially 153 patients were selected for possible inclusion 
in this study: 93 in Group D (with proven disc prolapse on 
MRI/CT) and 60 in Group N (without disc prolapse shown 
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Table 3 Specific symptoms before injections and at the time of questionnaire
Symptom Group D (n = 67) Group N (n = 43)
Before After P-value Symptoms 
resolved
Before After P-value Decreased with
Hamstring pain at rest 24 (36%) 9 (13%) 0.0045* 15 (63%) 14 (33%) 6 (14%) 0.07 8 (57%)
Calf pain at rest 12 (18%) 4 (6%) 0.06 8 (67%) 5 (12%) 2 (5%) 0.43 3 (25%)
Achilles/foot pain at rest 10 (15%) 7 (10%) 0.61 3 (30%) 3 (7%) 1 (2%) 0.62 2 (67%)
Back pain at rest 45 (67%) 28 (42%) 0.0053* 17 (38%) 21 (49%) 15 (35%) 0.27 6 (29%)
Hamstring pain during 
exercise
30 (45%) 15 (22%) 0.01* 15 (50%) 19 (44%) 4 (9%) 0.0005* 15 (79%)
Calf pain during exercise 14 (21%) 5 (8%) 0.0454* 9 (64%) 7 (16%) 2 (5%) 0.16 5 (71%)
Achilles/foot pain during 
exercise
10 (15%) 4 (6%) 0.16 6 (60%) 5 (12%) 2 (5%) 0.43 3 (60%)
Back pain during exercise 38 (57%) 25 (37%) 0.04* 13 (34%) 17 (40%) 16 (37%) 1.00 1 (6%)
Numbness 12 (18%) 7 (10%) 0.20 5 (42%) 7 (16%) 2 (5%) 0.16 5 (71%)
Muscle weakness 17 (25%) 6 (9%) 0.021* 11 (65%) 9 (21%) 5 (12%) 0.38 4 (44%)
Pins and needles 17 (25%) 6 (9%) 0.021* 11 (65%) 8 (19%) 4 (9%) 0.35 4 (50%)
Other symptoms 15 (22%) 9 (13%) 0.26 6 (40%) 10 (23%) 6 (14%) 0.41 4 (40%)
Note: *denotes statistically significant decrease after injection (P , 0.05).
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or other obvious cause of nerve-impingement on MRI/CT). 
Follow-up was achieved for 71% of Group D (67 patients) 
and 74% of Group N (43 patients). Comparison of the full 
groups of those followed-up was made as no significant 
differences in characteristics were noted between the initial 
groups and the follow-up groups (Table 1).
Fisher’s exact tests and unpaired t-tests showed no 
signif icant differences in most patient characteristics 
between Groups D and N after follow-up (Table 2). Age 
was 41 years ± 12.8 (mean ± standard deviation [SD]) in 
Group D and 46 years ± 13.2 in Group N, which was sig-
nificantly higher. The period of time between injection and 
follow-up was 30 months ± 18 (mean ± SD) for Group D and 
33 months ± 18 for Group N. Most injections were performed 
at L5/S1 (51% of the patients in both groups) and L4/5 (40% 
of patients in Group D and 45% in Group N), and a small 
number at L3/4 (9% in Group D and 3% in Group N).
Several specific symptoms for Group D had decreased 
 signif icantly, for Group N these symptoms had also 
decreased with quite high percentages, just not significantly. In 
decrease-rates, one significant difference was noted between 
Groups D and N; back pain during exercise had decreased sig-
nificantly more in Group D (P = 0.002). Hamstring pain during 
exercise, the symptom in the lower-limbs with the highest preva-
lence, had decreased significantly in both groups (Table 3).
No significant differences were found between Group D 
and N for patients opinions on: improvement of symptoms 
(Table 4), effect of injections on this improvement (Table 5) and 
whether they would have the same procedure done knowing 
what they now know (Table 6).
Almost one third of both groups (Group D: 28%/Group N: 
32%) noted they were completely cured and exercising as 
much as before. Two other groups noted their symptoms were 
much better (Group D: 30%/Group N: 16%) and slightly better 
(Group D: 13%/Group N: 26%). Overall symptoms of 71% of 
patients in Group D and 74% of patients in Group N were at 
least slightly better at the time of the questionnaire compared 
to just before injections. Eight percent of Group D and 7% of 
Group N had no more pain but were not exercising as much 
as they used to. A fairly large group noted the symptoms were 
similar to before the injections (Group D: 16% and Group N: 
12%) and a small percentage actually noted slight or much 
worsening of symptoms (respectively: Group D: 2%/Group 
N: 2% and Group D: 3%/Group N: 5%) (Table 4).
Twelve percent of Group D and 14% of Group N were 
certain the actual injection had fully cured their condition. 
Another 15% of Group D and 9% of Group N were certain 
the injections had improved their symptoms in the long term 
Table 2 Comparisons between the follow-up groups for patients 
with and without a disc prolapse on imaging
Group D 
(n = 67)
Group N 
(n = 43)
P-value 
(SE)
Age in years (mean ± SD) 41 ± 12.8 46 ± 13.6 0.05 (2.56)
Male 46 (69%) 30 (70%) 1.00
Elite athlete 29 (43%) 14 (33%) 0.32
Total number of athletes 51 (76%) 36 (84%) 0.47
Level of injection
 L3–L4 6 (9%) 2 (4%) 0.48
 L4–L5 27 (40%) 19 (45%) 0.70
 L5–S1 34 (51%) 22 (51%) 1.00
Length of follow-up in months  
(mean ± SD)
30 ± 18 33 ± 18 0.40 (3.52)
Abbreviations: SD, standard deviation; SE, standard error.
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but did not fully cure them. Adding up, a fairly large group 
of patients (Group D: 27%/Group N: 24%) was certain the 
injections had improved their symptoms in the long term. 
Another 8% of Group D and 14% of Group N thought the 
injections may have been helpful in the long term.
A similarly large proportion of patients who noted 
improvement indicated that the injection certainly had 
improved their symptoms, but noted that the effects had been 
non-lasting (Group D: 28%/Group N: 30%). Because of this 
only short-term lasting effect, one third would not have the 
procedure done for the same symptoms.
Another group (Group D 15%/Group N: 12%) thought 
the injections had played no role whatsoever in their improve-
ment. Asked whether they would have the same procedure 
done, one third of these patients noticeably did answer yes. 
One person in Group D and one in Group N did report even-
tual improvement in symptoms but, despite this, thought the 
injections had actually worsened their symptoms.
Of the patients who thought their symptoms were 
unchanged (Group D: 16%/Group N: 12%), 50% thought the 
injections had worked in the short term but that the effects 
were non-lasting (Group D: 6%/Group N: 7%). The patients 
who had worsening of symptoms did think the injections had 
worked for them but only in the short term. In the end, none 
of these patients blamed the injections for their worsening.
Importantly, as said before, no significant differences 
were noted between the main Groups D and N. Male and elite 
patients, however, answered significantly more often (with 
significance of respectively P = 0.01 and P = 0.04) that they 
were completely cured and were exercising as before and 
that their symptoms had improved. No significant difference 
was noted however in what they and their counter-subgroups 
thought about the effect of the injections on their improve-
ment, or whether they would have the same procedure done 
for the same symptoms. Subgroups older/younger than 30 
did not show any significant differences.
Table 4 Answers to question 3: How much better or worse are the symptoms now compared to just before the injection?
Group D 
(n = 67)
Group N 
(n = 43)
P-value Male 
(n = 76)
Female 
(n = 34)
P-value Elite 
(n = 43)
Non-elite 
(n = 67)
P-value
Completely cured and 
exercising as before
19 (28%) 14 (32%) 0.67 29 (38%) 4 (12%) 0.01* 18 (42%) 15 (22%) 0.04
No pain but not exercising  
as much 
5 (8%) 3 (7%) 1.00 5 (7%) 3 (9%) 0.70 3 (7%) 5 (8%) 1.00
Much better 20 (30%) 7 (16%) 0.12 15 (20%) 12 (35%) 0.09 9 (21%) 18 (27%) 0.51
Slightly better 9 (13%) 11 (26%) 0.13 15 (20%) 5 (15%) 0.60 6 (14%) 14 (21%) 0.45
Similar 11 (16%) 5 (12%) 0.59 10 (13%) 6 (18%) 0.57 7 (16%) 9 (13%) 0.78
Slightly worse 1 (2%) 1 (2%) 1.00 1 (1%) 1 (3%) 0.53 0 (0%) 2 (3%) 0.52
Much worse 2 (3%) 2 (5%) 0.64 1 (1%) 3 (9%) 0.09 0 (0%) 4 (6%) 0.15
Note: *denotes statistically significant decrease after injection (P , 0.05).
Table 5 Extent to which the injections contributed to improvement in patient groups with: “improvement of symptoms”, “similar 
symptoms compared to before the injections”, and “worsening of symptoms”
Group D 
(n = 67)
Group N 
(n = 43)
P-value of 
whole group
P-value 
intragroup
5.1 Patients who noted improvement in symptoms: n = 53 (79%) n = 35 (81%) 0.81 X
Completely cured as a result of injection 8 (12%) 6 (14%) 0.78 1.00
Certain injection improved symptoms in long term 10 (15%) 4 (9%) 0.56 0.39
Injection may have improved symptoms in long term 5 (8%) 6 (14%) 0.33 0.53
Certain injection improved symptoms but effects were non-lasting 19 (28%) 13 (30%) 0.83 0.83
Certain the Injection didn’t do anything 10 (15%) 5 (12%) 0.78 0.77
Injection may have worsened symptoms 1 (2%) 0 (0%) 1.00 1.00
Certain injection worsened symptoms 0 (0%) 1 (3%) 1.00 0.40
5.2 Patients whose symptoms were similar to before injections: n = 11 (16%) n = 5 (12%) 0.59 X
Certain injection improved symptoms but effects were non-lasting 4 (6%) 3 (7%) 1.00 1.00
Certain the Injection didn’t do anything 7 (10%) 2 (5%) 0.48 1.00
5.3 Patients whose symptoms had worsened: n = 3 (5%) n = 3 (7%) 0.68 X
Certain injection improved symptoms but effects were non-lasting 2 (3%) 1 (2%) 1.00 1.00
Certain the injection didn’t do anything 1 (2%) 2 (5%) 0.56 0.56
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Other factors which may have contributed to 
improvement were named by 61% of Group D and 47% 
of Group N. Most named treatments were physiotherapy 
(Group D: 40%/Group N: 42%), massage therapy (Group D: 18%/
Group N: 16%) and chiropractic/osteopathy (Group D: 15%/ 
Group N: 9%).
One significant difference (P = 0.0007) was noted 
between Groups D and N: 19% of the patients with disc 
prolapse (Group D) went on to have surgery, compared to 
5% in the group without disc prolapse (Group N) (Table 7). 
It is obvious that patients who went on to have surgery did 
so because symptoms did not improve after therapy with 
cortisone injections. A comparison between the group of 
patients who had undergone surgery after the injections 
and those who did not, confirmed this (Table 8). This might 
have had an influence on the eventual improvement of 
symptoms but not so much on what patients thought about 
the effect the injections had on this improvement.
Side effects were experienced by 70% of Group D and 
by 81% of Group N. No significant differences between 
Groups D and N were noted. The most common side effect 
was severe or moderate pain from injection (Group D: 22%/
Group N: 14%). Less common side effects were: muscle 
cramps, an affected regularity of menstruation cycle, head-
ache, allergic reaction, dizziness, and sleepiness (Table 9).
Discussion
As MRI technology has improved over the past decades, an 
increasing number of hamstring injuries are being proven to 
in fact be muscle strains sited in the lower-limbs themselves. 
Despite this, there remain a significant number of suspected 
hamstring injuries that continue to be MRI-negative.1 Pos-
sible causes of the patient’s pain in these circumstances 
include: extraforaminal entrapment of lumbosacral nerves,3 
piriformis syndrome,6,7 and hamstring syndrome.8
Several other tissues surrounding the nerve-roots have the 
potential to cause nerve root impingement and inflammation in 
a similar way as a prolapsed disc can, as Briggs and Chandraraj 
showed for the lumbosacral ligament.12 The slightest irritation 
of the nerve roots may cause irritation and symptoms in the 
lower-limbs. This may not be detectable on MRI or CT and 
could therefore explain how the patients without prolapse 
or other obvious cause of nerve impingement on MRI/CT, 
and where no specific anatomical diagnosis of injury can be 
made in the lower-limb itself, do develop lower-limb pain. 
In some cases, nerve-impingement can be detected but no 
definite cause is shown (Figure 2). In the case of Figure 2, 
for example, it was thought by the clinicians that perhaps the 
thecal sac was being impinged by its expansion into the neural 
foramen, although this is speculative.
As pathology may be similar in patients with suspected 
back-related lower-limb pain, without prolapse or other obvious 
cause of nerve impingement shown on MRI/CT; and patients 
with assumed back-related lower-limb pain, with shown pro-
lapse on MRI/CT, cortisone injections, which have been proven 
to be useful in the second group, may be just as useful in the 
group without shown prolapse. For this group, no definite help 
has been proven in earlier studies but good results have been 
Table 6 Answers to question 7: “would you have the same procedure done for the same symptoms knowing what you now know?”
Group D 
(n = 67)
Group N 
(n = 43)
P-value Male 
(n = 76)
Female 
(n = 34)
P-value Elite 
(n = 43)
Non-elite 
(n = 67)
P-value
Yes, it was worth it 43 (64%) 29 (67%) 0.84 53 (70%) 19 (56%) 0.20 30 (70%) 42 (63%) 0.54
No, because of expenses/side effects 4 (6%) 0 (0%) 0.15 2 (3%) 1 (3%) 1.00 1 (2%) 2 (3%) 1.00
No, because the effects didn’t last very long 7 (10%) 7 (16%) 0.78 9 (12%) 5 (15%) 0.76 3 (7%) 11 (16%) 0.24
No because it was not helpful at all 13 (19%) 7 (16%) 0.80 12 (16%) 9 (27%) 0.76 9 (21%) 12 (18%) 0.81
Table 7 Other treatments used
Treatment Group D (n = 67) Group N (n = 43) P-value Total (n = 110)
Physiotherapy 27 (40%) 18 (42%) 1.00 45 (41%)
Massage 12 (18%) 7 (16%) 1.00 19 (17%)
Chiropractic/osteopathy 10 (15%) 4 (9%) 0.56 14 (13%)
Surgery 13 (19%) 2 (5%) 0.0007* 15 (14%)
Other medication 2 (3%) 0 (0%) 0.52 2 (2%)
Cessation of aggravating activities 6 (9%) 7 (16%) 0.36 13 (12%)
Other 15 (22%) 4 (9%) 0.12 19 (17%)
Total number of patients receiving other treatments 41 (61%) 20 (47%) 0.17 61 (56%)
Note: *denotes statistically significant decrease after injection (P , 0.05).
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experienced in practice in a sports medicine setting in Australia. 
Furthermore, for similar peripheral pathology as carpal tunnel 
syndrome13,14 and Morton’s neuroma,15 cortisone-injections 
have already shown to be helpful.
In this study no significant differences were found 
between the group with proven prolapse (Group D) and the 
group without proven prolapse or other obvious cause of 
impingement (Group N), in the way patients had improved, 
what effect the injections had had in this improvement, 
and whether they would have this injection done again 
for the same symptoms. Thirteen percent of the patients 
indicated the injections had completely cured their symp-
toms and altogether nearly one third of the patients were 
certain the injections had improved their symptoms in 
the long term. Another one third of all patients thought 
the symptoms  certainly were affected, however only in 
the short term. This short term effect has been noted in 
other studies before.7 Two patients thought the injections 
had actually caused a temporary worsening in symptoms. 
The remaining patients did not notice any effect of the 
injections at all.
A significantly higher percentage of the “elite” and 
“male” subgroups were completely cured, and exercis-
ing as much as before, compared to the “non-elite” and 
“female” subgroups. The opinion however on the effect of 
injections on improvement and whether they would have 
the procedure done for the same symptoms again did not 
differ between these subgroups. Most of the elite athletes 
were in fact males (79%) so the patients that caused this 
bias mainly belonged to one group; the male elite athletes. 
Possible reasons for these differences in outcome may be 
that elite athletes may get more medical attention and have 
better training and rehabilitation possibilities. As quite a 
large proportion of people in this study were elite athletes, 
this did probably influence the outcome. The percentage 
of elite athletes however was the same for Group D and N 
so this would not have influenced the comparison between 
Groups D and N.
This study was not a randomized control trial (RCT) 
but a retrospective case series and therefore does not 
have a very high level of evidence (level 3). Further-
more, follow-up time was quite spread out for this 
study. However, patients had the option to note they 
only had short-term effects. Patients who noted this 
had the same average follow-up time as the rest of the 
patients. Thirdly, all outcomes were based on opinions 
of the patients, so no detailed data on pain scores has 
been collected.
Conclusion
The most important aspect of the outcome of this study 
was that no significant differences were found between the 
group for which the injections have been proven to be helpful 
(Group D, with shown prolapse on MRI/CT) and the group for 
which this effect has not yet been proven (Group N, without 
shown prolapse or other obvious cause of nerve-impingement 
on MRI/CT),for improvement of symptoms. There was no 
difference between the groups for either symptom improve-
ment, effect of injections on this improvement, and whether 
they would have the same procedure done again knowing 
what they now know.
This might suggest a potential role for the use of trans-
foraminal corticosteroid injections for patients with non-
specific exercise-related lower-limb pain, without prolapse 
or other obvious cause of impingement shown on MRI/CT, 
Table 9 Reported side effects
Group D (n = 67) Group N (n = 43) P-value Total (n = 110)
None 47 (70%) 35 (81%) 0.26 75%
Moderate pain from injection 8 (12%) 5 (11%) 1.00 12%
Severe pain from injection 7 (10%) 1 (2%) 0.15 7%
Allergic reaction 1 (2%) 1 (2%) 1.00 2%
Sweating/dizziness 1 (2%) 1 (2%) 1.00 2%
Headache 1 (2%) 0 (0%) 1.00 1%
Other 6 (9%) 1 (2%) 0.24 6%
Table 8 Answers to question 7 “would you have the same 
procedure done for the same symptoms knowing what you now 
know?” for the “Surgery” and “No Surgery” groups
Surgery  
(n = 15)
No surgery  
(n = 95)
P-value
No, because it was not helpful 
at all
8 (53%) 13 (14%) 0.00*
No, because effects didn’t last 
very long
3 (20%) 11 (12%) 0.40
No, because of expenses/side 
effects
0 (0%) 3 (3%) 1.00
Yes, because it was worth it 4 (27%) 68 (72%) 0.003
Note: *denotes statistically significant decrease after injection (P , 0.05).
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and at least suggests more research should be done on this 
treatment for this specific cause.
Future studies on this subject should preferably be RCTs 
with a higher number of patients included. In this way the 
effect of this treatment for these specific symptoms can be 
more thoroughly investigated and actual conclusions drawn 
for future use of this treatment.
Disclosure
The authors report no conflicts of interest in this work other 
than the receipt of private consultation fees for treatment of 
patients in the study.
References
1. Verrall G, Slavotinek J, Barnes P, et al. Clinical risk factors for ham-
string muscle strain injury: a prospective study with correlation of 
injury by magnetic resonance imaging. Br J Sports Med. 2001;35: 
435–440.
2. Orchard J, Marsden J, Lord S, et al. Preseason hamstring muscle  weakness 
associated with hamstring muscle injury in Australian footballers. Am J 
Sports Med. 1997;25:81–85.
3. Bennell K, Wajswelner H, Lew P, et al. Isokinetic strength testing does 
not predict hamstring injury in Australian Rules footballers. Br J Sports 
Med. 1998;32:309–314.
4. Buenaventura RM, Datta S, Abdi S, et al. Systematic review of  therapeutic 
lumbar transforaminal epidural steroid injections. Pain Physician. 
2009;12:233–251.
 5. Lich LC, Sell P. Outcomes of a prospective cohort study on  peri-radicular 
infiltration for radicular pain in patients with lumbar disc herniation 
and spinal stenosis. Eur Spine J. 2004;13:325–329.
 6. Parziale JR, Hudgins TH, Fishman LM. The piriformis syndrome. 
Am J Orthop. 1997;26:316–318.
 7. Boyajian-O’Neill LA, McClain RL, Coleman MK, et al. Diagnosis 
and management of piriformis syndrome: an osteopathic approach. 
J Am Osteopath Assoc. 2008;657–664.
 8. Puranen J, Orava S. The hamstring syndrome – a new gluteal sciatica. 
Ann Chir Gynaecol. 1991;80:212–214.
 9. Szalai K, Illyés A. Sacral epidural steroid injections used for the 
prevention of hamstring injuries. Physical Education and Sport. 
2005;3:37–44.
 10. Karppinen J, Ohinmaa A, Malmivaara A, et al. Cost effec-
tiveness of periradicular inf iltration for sciatica: subgroup 
analysis of a randomized controlled trial. Spine. 2001;26: 
2587–2595.
 11. Vad VB, Bhat AL, Lutz GE, et al. Transforaminal epidural steroid injec-
tions in lumbosacral radiculopathy: a prospective randomized study. 
Spine. 2002;27:11–16.
 12. Briggs CA, Chandraraj S. Variations in the lumbosacral ligament and 
associated changes in the lumbosacral region resulting in compres-
sion of the fifth dorsal root ganglion and spinal nerve. Clin Anat. 
1996;9:278–279.
 13. Lee JH, An JH, Lee SH, et al. Effectiveness of steroid injection in treat-
ing patients with moderate and severe degree of carpal tunnel syndrome 
measured by clinical and electrodiagnostic assessment. Clin J Pain. 2009; 
25:111–115.
 14. Gurcay E, Unlu E, Gurcay A, et al. Evaluation of the effect of local 
corticosteroid injection and anti-inflammatory medication in carpal 
tunnel syndrome. Scott Med J. 2009;54:4–6.
 15. Bennett GL, Graham CE, Mauldin DM. Morton’s interdigital neuroma: a 
comprehensive treatment protocol. Foot Ankle Int. 1995;16:760–763.
A MRI T1 L5/S1 B MRI T2 L5/S1
Figure 2 Nerve impingement without prolapse on MRI. The arrow shows the nerve impingement in absence of a prolapse, as described.
